'Damning' FDA inspection report undermines Alzheimer's drug.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 38484070.
- Also identified by DOI 10.1126/science.adp1964.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Inspectors faulted analyses of clinical trial samples by Hoau-Yan Wang for drug developer Cassava Sciences.
Medical subject headings
- Alzheimer Disease
- Scientific Misconduct
- Spiro Compounds
- United States Food and Drug Administration